Skip to main content

Table 3 Fold increase of LD50 in resistant cell lines for treatment with NAMPT inhibitors.

From: Target enzyme mutations are the molecular basis for resistance towards pharmacological inhibition of nicotinamide phosphoribosyltransferase

 

APO866

CHS-828

TP201565

NYH/CHS

18.3

168

33.5

HCT-116/APO866

946

414

1,723

HCT-116/TP201565

2,364

774

10,103

PC-3/TP201565

8,324

624

19,675

  1. The level of resistance of the resistant cell lines, NYH/CHS, HCT-116/APO866, HCT-116/TP201565 and PC-3/TP201565 is shown for treatment APO866, CHS-828 and TP201565. Values represent the ratio of LD50 of the resistant cell line:LD50 of parental cell line as measured by clonogenic survival assay.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us